TY - JOUR
T1 - Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice
AU - Kotanidou, Anastasia
AU - Loutrari, Heleni
AU - Papadomichelakis, Evangelos
AU - Glynos, Constantinos
AU - Magkou, Christina
AU - Armaganidis, Apostolos
AU - Papapetropoulos, Andreas
AU - Roussos, Charis
AU - Orfanos, Stylianos E.
N1 - Funding Information:
The authors are grateful to Mr. N. Economou for his technical assistance. This study was supported by the Thorax foundation and an unrestricted educational grant by Pharmaserve Lilly (SEO).
PY - 2006/8
Y1 - 2006/8
N2 - The serine protease activated protein C (APC) possesses prominent anticoagulant and anti-inflammatory actions. In this study, we investigated the effect of inhaled recombinant human (rh) APC in a murine lung injury model. Animals inhaled 10 mg of Pseudomonas lipopolysaccharide (LPS) in 3 mL normal saline (NS); 30 min prior to LPS, mice were pretreated with inhaled rhAPC (4 mg/3 mL NS; APC + LPS group) or NS (LPS group). A control animal group inhaled vehicle (NS) twice. 24 h later, total cells and cell-types, protein content, and the cytokines tumor necrosis factor-α, interleukin (IL)-6, macrophage inflammatory protein-1α, and mouse keratinocyte-derived chemokine (a homolog of human IL-8) were estimated in bronchoalveolar lavage fluid (BALF). Lung pathology given as total histology score (THS), wet/dry lung weight ratios, and lung vascular cell adhesion molecule (VCAM)-1 expression were additionally assessed. rhAPC inhalation attenuated the aerosolized LPS-induced increases of: total cells, neutrophils and macrophages in BALF, lung tissue VCAM-1 protein levels, and THS. Total protein levels and cytokines in BALF, and wet/dry weight ratios were increased in the LPS group, but rhAPC pretreatment did not significantly alter the LPS-induced responses. In conclusion, in this murine septic model of lung injury, inhaled rhAPC appears to attenuate lung inflammation, without reversing the observed increases in lung permeability and BALF cytokines. This effect may be associated with leukocyte trafficking modifications, related, at least in part, to VCAM-1 reduction.
AB - The serine protease activated protein C (APC) possesses prominent anticoagulant and anti-inflammatory actions. In this study, we investigated the effect of inhaled recombinant human (rh) APC in a murine lung injury model. Animals inhaled 10 mg of Pseudomonas lipopolysaccharide (LPS) in 3 mL normal saline (NS); 30 min prior to LPS, mice were pretreated with inhaled rhAPC (4 mg/3 mL NS; APC + LPS group) or NS (LPS group). A control animal group inhaled vehicle (NS) twice. 24 h later, total cells and cell-types, protein content, and the cytokines tumor necrosis factor-α, interleukin (IL)-6, macrophage inflammatory protein-1α, and mouse keratinocyte-derived chemokine (a homolog of human IL-8) were estimated in bronchoalveolar lavage fluid (BALF). Lung pathology given as total histology score (THS), wet/dry lung weight ratios, and lung vascular cell adhesion molecule (VCAM)-1 expression were additionally assessed. rhAPC inhalation attenuated the aerosolized LPS-induced increases of: total cells, neutrophils and macrophages in BALF, lung tissue VCAM-1 protein levels, and THS. Total protein levels and cytokines in BALF, and wet/dry weight ratios were increased in the LPS group, but rhAPC pretreatment did not significantly alter the LPS-induced responses. In conclusion, in this murine septic model of lung injury, inhaled rhAPC appears to attenuate lung inflammation, without reversing the observed increases in lung permeability and BALF cytokines. This effect may be associated with leukocyte trafficking modifications, related, at least in part, to VCAM-1 reduction.
KW - APC inhalation
KW - Acute lung injury
KW - Adhesion molecules
KW - LPS
KW - Neutrophils
UR - http://www.scopus.com/inward/record.url?scp=33748523789&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748523789&partnerID=8YFLogxK
U2 - 10.1016/j.vph.2006.06.016
DO - 10.1016/j.vph.2006.06.016
M3 - Article
C2 - 16959545
AN - SCOPUS:33748523789
SN - 1537-1891
VL - 45
SP - 134
EP - 140
JO - Vascular Pharmacology
JF - Vascular Pharmacology
IS - 2
ER -